drugset / Trial / NCT00858182

Study of Safety and Efficacy on New Peritoneal Dialysis Solutions

NCT00858182

Phase 2 Withdrawn Iperboreal Pharma Srl
Non-randomizedParallel-groupOpen-labelTreatment

Summary

A major challenge of peritoneal dialysis (PD) therapy is the development of glucose-sparing strategies able to provide an efficacious ultrafiltration (UF) profile. Study hypothesis is to evaluate the possibility to formulate PD solutions containing xylitol and L-carnitine as osmotic agents to partially replace glucose.

Timeline

Start
2009-05
Primary completion
2012-10
Completion
2013-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Glucose Unknown 0.5 % Other
Subject L-carnitine Other / unclassified 0.1 % Other
Subject Xylitol Small molecule 0.6 % Other
Subject Xylitol Small molecule 1.5 % Other